15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
17:33 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Worm and fly studies suggest selinexor could help treat ALS. In Caenorhabditis elegans and Drosophila models of ALS, the XPO1 inhibitor selinexor increased survival compared with vehicle. Next steps could...
22:42 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Trypanosome In vitro studies identified tetrahydrophthalazinone-based inhibitors of T. brucei PDEB1 that could help treat African trypanosomiasis. Chemical synthesis and in vitro activity and cell division assays of tetrahydrophthalazinone analogs yielded two compounds that...
18:26 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus; Gram-positive bacterial infection Worm, cell culture and mouse studies suggest that retinoid antibiotics can help treat methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacterial infections. Screening of a library of synthetic small molecules...
17:45 , Mar 28, 2018 |  BC Extra  |  Preclinical News

Brown researchers suggest retinoids as anti-MRSA antibiotic

In a paper published in Nature , researchers at Brown University and colleagues suggest that retinoids could be a new class of antibiotics, and developed an analog that could help treat methicillin-resistant Staphylococcus aureus infections....
00:53 , Mar 7, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on CLEC1A could help predict the risk of Aspergillus infections in stem cell transplant recipients. In 310 stem cell transplant donors and matched recipients, genomic sequencing and cumulative incident analysis identified...
07:00 , Apr 11, 2016 |  BioCentury  |  Regulation

Tolerable uncertainty

Acadia Pharmaceuticals Inc. may have found a sensitive endpoint for Nuplazid pimavanserin in a condition lacking good measures by adapting a validated but broader scale. Although an FDA advisory committee was uncertain how much real-world...
07:00 , Oct 1, 2015 |  BC Innovations  |  Tools & Techniques

NCATS's extracellular revolution

Two years into its five-year run, a $117.5 million NIH-funded consortium established to look for biomarkers and therapies stemming from extracellular RNA (exRNA) research is now moving into its testing and validation phase, after completing...
07:00 , Jun 15, 2015 |  BioCentury  |  Regulation

LDL in context

Discussion at last week's advisory committee meeting for the PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab suggest that, for first-in-class hypercholesterolemia candidates, the agency and the committee are leaning toward narrowing the use of LDL...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NLR family member X1 (NLRX1)

Pulmonary disease INDICATION: Chronic obstructive pulmonary disease (COPD) Studies in mice and patient samples suggest promoting NLRX1 could help treat cigarette smoke-induced COPD. Levels of NLRX1 mRNA were lower in lung tissue samples from patients...